by Barry101 | Feb 7, 2025 | Press Release
Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of Ampligen as an intranasal adjuvant increased immune response, including cross-protection via avian influenza antibody...
by Barry101 | Feb 5, 2025 | Press Release
Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting toxicities Enrollment for Phase 2 expected to commence imminently...
by Barry101 | Jan 23, 2025 | Press Release
OCALA, Fla., Jan. 23, 2025 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate the Efficacy and Safety of Ampligen in Patients With...
by Barry101 | Jan 22, 2025 | Press Release
Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS The early-onset broad-spectrum antiviral effect of Ampligen has been observed to stimulate strong innate immune response,...
by Barry101 | Jan 15, 2025 | Press Release
– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces – Expected milestones over the course of the next 18 months...
